B M Meyers1, J Knox2, R Cosby3, J R Beecroft4, K K W Chan5, N Coburn5, J Feld6, D Jonker7, A Mahmud8, J Ringash2,9. 1. Juravinski Cancer Centre, Department of Oncology, McMaster University, Hamilton, ON. 2. Princess Margaret Cancer Centre, Toronto, ON. 3. Program in Evidence-Based Care, Department of Oncology, McMaster University, Hamilton, ON. 4. Department of Medical Imaging, Mount Sinai Hospital, and University Health Network, Toronto, ON. 5. Sunnybrook Odette Cancer Centre, Toronto, ON. 6. Toronto General Hospital Research Institute, Toronto, ON. 7. The Ottawa Hospital Cancer Centre, Ottawa, ON. 8. Cancer Centre of Southeastern Ontario, Kingston, ON. 9. Department of Radiation Oncology, University of Toronto, Toronto, ON.
Abstract
Background: Practice guidelines based on a systematic review of the literature regarding the nonsurgical management of hepatocellular carcinoma (hcc) in North America are lacking. Resection and transplantation are the foundations for cure of hcc; however, most patients are diagnosed at an advanced stage, precluding those curative treatments. A number of local or regional therapies are used and are followed by systemic therapy for advanced or progressive disease. Other treatments are available, but their efficacy, compared with those standards, is not well known. Methods: First, systematic review questions were developed. Literature searches of the medline, embase, and Cochrane library databases (January 2000 to July 2018 or January 2005 to July 2018 depending on the question) were conducted; in addition, abstracts from the 2018 annual meeting of the American Society of Clinical Oncology were reviewed. A practice guideline was drafted that was then scrutinized by internal and external reviewers. Results: Seventy-seven studies were included in the guideline: no guidelines, two systematic reviews, and seventy-five primary studies published in full (including one pooled analysis). Five recommendations were developed. Conclusions: There is no evidence for or against the use of local or regional interventions other than transarterial chemoembolization for the treatment of intermediate- or advanced-stage hcc. Furthermore, there is no evidence to support the addition of sorafenib to any local or regional therapy. Sorafenib or lenvatinib are recommended for first-line systemic treatment of intermediate-stage hcc. Regorafenib or cabozantinib provide survival benefits when given as second-line treatment. Antiviral treatment is recommended in individuals with advanced hcc who are positive for the hepatitis B surface antigen. 2020 Multimed Inc.
Background: Practice guidelines based on a systematic review of the literature regarding the nonsurgical management of hepatocellular carcinoma (hcc) in North America are lacking. Resection and transplantation are the foundations for cure of hcc; however, most patients are diagnosed at an advanced stage, precluding those curative treatments. A number of local or regional therapies are used and are followed by systemic therapy for advanced or progressive disease. Other treatments are available, but their efficacy, compared with those standards, is not well known. Methods: First, systematic review questions were developed. Literature searches of the medline, embase, and Cochrane library databases (January 2000 to July 2018 or January 2005 to July 2018 depending on the question) were conducted; in addition, abstracts from the 2018 annual meeting of the American Society of Clinical Oncology were reviewed. A practice guideline was drafted that was then scrutinized by internal and external reviewers. Results: Seventy-seven studies were included in the guideline: no guidelines, two systematic reviews, and seventy-five primary studies published in full (including one pooled analysis). Five recommendations were developed. Conclusions: There is no evidence for or against the use of local or regional interventions other than transarterial chemoembolization for the treatment of intermediate- or advanced-stage hcc. Furthermore, there is no evidence to support the addition of sorafenib to any local or regional therapy. Sorafenib or lenvatinib are recommended for first-line systemic treatment of intermediate-stage hcc. Regorafenib or cabozantinib provide survival benefits when given as second-line treatment. Antiviral treatment is recommended in individuals with advanced hcc who are positive for the hepatitis B surface antigen. 2020 Multimed Inc.
Authors: Lorenza Rimassa; Eric Assenat; Markus Peck-Radosavljevic; Marc Pracht; Vittorina Zagonel; Philippe Mathurin; Elena Rota Caremoli; Camillo Porta; Bruno Daniele; Luigi Bolondi; Vincenzo Mazzaferro; William Harris; Nevena Damjanov; Davide Pastorelli; María Reig; Jennifer Knox; Francesca Negri; Jörg Trojan; Carlos López López; Nicola Personeni; Thomas Decaens; Marie Dupuy; Wolfgang Sieghart; Giovanni Abbadessa; Brian Schwartz; Maria Lamar; Terri Goldberg; Dale Shuster; Armando Santoro; Jordi Bruix Journal: Lancet Oncol Date: 2018-04-03 Impact factor: 41.316
Authors: G K Abou-Alfa; S Qin; B-Y Ryoo; S-N Lu; C-J Yen; Y-H Feng; H Y Lim; F Izzo; M Colombo; D Sarker; L Bolondi; G Vaccaro; W P Harris; Z Chen; R A Hubner; T Meyer; W Sun; J J Harding; E M Hollywood; J Ma; P J Wan; M Ly; J Bomalaski; A Johnston; C-C Lin; Y Chao; L-T Chen Journal: Ann Oncol Date: 2018-06-01 Impact factor: 32.976
Authors: Simon Chun Ho Yu; Joyce Wai Yi Hui; Edwin Pun Hui; Stephen Lam Chan; Kit Fai Lee; Frankie Mo; John Wong; Brigette Ma; Paul Lai; Tony Mok; Winnie Yeo Journal: Radiology Date: 2013-10-28 Impact factor: 11.105
Authors: G P Browman; T E Newman; E A Mohide; I D Graham; M N Levine; K I Pritchard; W K Evans; J A Maroun; D I Hodson; M S Carey; D H Cowan Journal: J Clin Oncol Date: 1998-03 Impact factor: 44.544
Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245
Authors: Melanie B Thomas; Elizabeth Garrett-Mayer; Munazza Anis; Kate Anderton; Tricia Bentz; Andie Edwards; Alan Brisendine; Geoffrey Weiss; Abby B Siegel; Johanna Bendell; Ari Baron; Vinay Duddalwar; Anthony El-Khoueiry Journal: Oncology Date: 2018-05-02 Impact factor: 2.935
Authors: L Cardarelli-Leite; A Hadjivassiliou; D Klass; J Chung; S G F Ho; H J Lim; P T W Kim; A Mujoomdar; D M Liu Journal: Curr Oncol Date: 2020-11-01 Impact factor: 3.677